Compare Moderna, Inc. (MRNA) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Atlassian Corporation PLC — how do they compare? Moderna, Inc. trades at $225.2 (market cap $78.65B), while Atlassian Corporation PLC trades at $206.79 (market cap $51.53B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is more actively traded (37,373,437 versus 2,904,511). Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Atlassian Corporation PLC for 65 Days on average.
| MRNA | TEAM | |
|---|---|---|
Market Cap | $78.65B | $51.53B |
Volume | 37,373,437 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $203.46 | $203.57 |
52-Week Low | $22.36 | $57.15 |
Typical Hold Time | 59 Days | 65 Days |
Enterprise Value | $74.80B | $51.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Atlassian (TEAM) trades at $206.79, up 5.68% with strong bullish momentum. The stock shows robust technical strength with moving averages signaling buy and price above key resistance levels. Fundamentally, revenue growth continues at $5.22B (2025) with improving margins, though the company remains unprofitable. Recent earnings beats and strong analyst consensus (69.77% buy ratings) support the positive sentiment, while AI-driven product adoption and cloud migration provide growth catalysts.
The outlook remains positive with AI adoption and cloud growth driving momentum, though valuation metrics appear stretched with negative profitability. Key risks include high P/S ratio (8.06), competitive pressures, and execution challenges in maintaining growth trajectory. The consensus price target of $191.16 suggests potential downside from current levels despite strong fundamental improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
